Oral Minoxidil vs topical Minoxidil

What was the trial comparing oral and topical Minoxidil?

Penha and colleagues published a double-blind, placebo-controlled randomised trial in JAMA Dermatology in 2024, comparing oral Minoxidil 5 mg once daily against topical Minoxidil 5 percent twice daily in men with androgenetic alopecia. Ninety men were randomised, 45 per arm, 68 completed the 24 weeks, and the primary outcome was terminal hair density.

Did the trial find oral Minoxidil more effective than topical Minoxidil?

No, superiority was not demonstrated: differences in terminal hair density were 3.1 hairs/cm² frontally and 23.4 hairs/cm² at the vertex, neither statistically significant. A secondary photographic assessment favoured oral Minoxidil at the vertex by 24 percent (confidence interval 0 to 48) but showed no frontal difference, a hint rather than a finding.

Superiority was not demonstrated. Between-group differences in terminal hair density were 3.1 hairs/cm² frontally (p = .27) and 23.4 hairs/cm² at the vertex (p = .09), neither statistically significant.

A secondary photographic assessment favoured the tablet at the vertex, a 24 percent difference with a 95 percent confidence interval of 0 to 48 (p = .04), and showed no difference frontally. A confidence interval touching zero on a secondary endpoint is a hint, not a finding.

How did the side effects of oral and topical Minoxidil differ in the trial?

In the trial, oral Minoxidil caused hypertrichosis in 49 percent of patients and headache in 14 percent, while topical Minoxidil caused hypertrichosis in 25 percent, scalp eczema in 16 percent and itching in 11 percent. More participants discontinued the topical treatment than the oral treatment because of side effects, three versus one.

• Oral: hypertrichosis 49 percent, headache 14 percent
• Topical: hypertrichosis 25 percent, scalp eczema 16 percent, itching 11 percent
• More participants discontinued topical treatment than oral treatment because of side effects, three versus one

What is the practical takeaway from comparing oral and topical Minoxidil?

Oral Minoxidil was not shown to outperform a product available without a prescription. What it removes is the daily application problem, the most common reason topical treatment fails in practice, which makes adherence its real argument, alongside its systemic side-effect profile as the trade-off.

Our full low-dose oral Minoxidil review covers dosing, safety and the consensus guidance.

Sources

1. Gupta AK, et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia. Skin Appendage Disorders, 2022. pmc.ncbi.nlm.nih.gov/articles/PMC9485924
2. Vano-Galvan S, et al. Safety of low-dose oral Minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of Dermatology, 2021. pubmed.ncbi.nlm.nih.gov/33639244
3. Penha MA, Miot HA, Kasprzak M, Muller Ramos P. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatology, 2024. pmc.ncbi.nlm.nih.gov/articles/PMC11007651
4. Akiska YM, Mirmirani P, Roseborough I, Mathes E. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement. JAMA Dermatology, 2025;161(1):87-95. pubmed.ncbi.nlm.nih.gov/39565602

This article summarises published research. It is general educational information, not medical advice, and it is not a recommendation to start, stop or change any medication. Prescription drugs carry contraindications and interactions; discuss them with a doctor who knows your medical history.